Dataset Information

Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression.

ABSTRACT:

Background

The distinct expression pattern of tumour-associated antigens (TAAs) might be a critical reason for the inefficacy of immunity-based treatments and heterogeneous postsurgical recovery in patients with solid tumours, including hepatocellular carcinoma (HCC). However, little is known about the clinical value of the coexpression patterns of multiple TAAs.

Methods

We determined the expression of multiple TAAs with identified immunogenicity (GPC3, AFP, SSX-2, NY-ESO-1, EpCAM, midkine) and the density of tumour-infiltrating immune cells by immunohistochemistry in a panel of 362 primary HCC patients. We evaluated the association between the TAAs, immune cell infiltration, clinicopathological parameters, and prognosis.

Results

Patients who coexpressed more TAAs had better prognosis (P<0.00001, overall survival). The integrated pattern of TAA was associated with good differentiation and small tumour size, and with more CD57(+) natural killer and CD20(+) B-cell infiltration (P<0.05). Multivariate Cox proportional hazards analysis identified the TAA index as an independent prognostic indicator (hazard ratio 0.625; 95% confidence interval 0.467-0.837; P=0.002), and could further predict patient prognosis in collaboration with local immune infiltration.

Conclusion

Our results could provide new evidence for the improvement of prognostic molecular signatures in HCC, and a novel rationale for patient enrolment in future immunotherapeutic trials and/or clinical treatments.

SUBMITTER: Liang J

PROVIDER: S-EPMC3749565 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression.

Liang J J Ding T T Guo Z-W ZW Yu X-J XJ Hu Y-Z YZ Zheng L L Xu J J

British journal of cancer 20130718 4

<h4>Background</h4>The distinct expression pattern of tumour-associated antigens (TAAs) might be a critical reason for the inefficacy of immunity-based treatments and heterogeneous postsurgical recovery in patients with solid tumours, including hepatocellular carcinoma (HCC). However, little is known about the clinical value of the coexpression patterns of multiple TAAs.<h4>Methods</h4>We determined the expression of multiple TAAs with identified immunogenicity (GPC3, AFP, SSX-2, NY-ESO-1, EpCAM ...[more]

PMID: 23868000

Similar Datasets

Project description:BackgroundThis study sought to explore the role of cell division cycle-associated protein 4 (CDCA4) in liver hepatocellular carcinoma (LIHC) patients.MethodsThe RNA-sequencing raw count data and the respective clinical information of 33 different LIHC cancer and normal tissues were collected from the Genotype Tissue Expression (GTEX) and The Cancer Genome Atlas (TCGA) databases. The expression of CDCA4 in LIHC was determined via the University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN) database. The PrognoScan database was used to examine the correlation between CDCA4 and overall survival (OS) in LIHC. The interaction between the potential upstream microRNAs and the long non-coding RNAs (lncRNAs) and CDCA4 was explored using the Encyclopedia of RNA Interactomes (ENCORI) database. Finally, the biological role of CDCA4 in LIHC was investigated by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG)analyses.ResultsCDCA4 RNA expression was elevated in the LIHC tumor tissues and linked to adverse clinical characteristics. It was also upregulated in most tumor tissues in the GTEX and TCGA data sets. According to the receiver operating characteristic (ROC) curve analysis, CDCA4 is a potential a biomarker for the diagnosis of LIHC. According to the Kaplan-Meier (KM) curve analysis, patients with LIHC in TCGA data set with low expression levels of CDCA4 had better than high expression levels in OS, disease-specific survival (DSS), and progression free interval (PFI). The gene set enrichment analysis (GSEA) suggested that CDCA4 mainly affected the biological events of LIHC by participating in the cell cycle, T cell receptor signaling pathway, DNA replication, glucose metabolism, and mitogen activated protein kinase (MAPK) signaling pathway. Based on the competing endogenous RNA concept and the correlation, expression, and survival analysis results, we believe that LINC00638/hsa miR-29b-3p/CDCA4 should be a potential regulatory pathway in LIHC.ConclusionsThe low expression of CDCA4 significantly improves the prognosis of LIHC patients, and CDCA4 is a potential new biomarker for LIHC prognosis prediction. CDCA4-mediated LIHC carcinogenesis may involve tumor immune evasion and anti-tumor immunity. LINC00638/hsa-miR-29b-3p/CDCA4 should be a potential regulatory pathway in LIHC, and these findings provide a new perspective for the development of anti-cancer strategies in LIHC.

Dataset Information

Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression.

Background

Methods

Results

Conclusion

Publications

Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets